[Fluorouracil, mitomycin-C and adriamycin in the treatment of metastasizing gastrointestinal adenocarcinomas].
28 patients with advanced adenocarcinomas were treated with combinations of 5-fluorouracil and mitomycin-C (FM, 21 patients) or of 5-fluorouracil, adriamycin and mitomycin-C (FAM, 7 patients). 5 patients responded, 3 showing an objective response of more than 50% lasting 3-5 months. Toxicity was primarily hematologic, chiefly comprising severe thrombopenias. The results indicate that with these combinations a limited palliative effect can be achieved in only a few patients.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D004317:Doxorubicin / Q000627:therapeutic use*; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008937:Mitomycins / Q000627:therapeutic use*
D008937:Mitomycins; D004317:Doxorubicin; D005472:Fluorouracil
Fluorouracil, Mitomycin-C und Adriamycin in der Behandlung metastasierender gastrointestinaler Adenokarzinome.